|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG_2 cell line显示文摘AIM: To investigate the role of DNA-PKcs subunits inradiosensitization by hyperthermia on hepatocellularcarcinoma HepG2 cell lines.METHODS: Hep G2 cells were exposed to hyperthermiaand irradiation. Hyperthermia was given at 45.5 ℃Cellsurvival was determined by an in vitro clonogenic assay forthe cells treated with or without hyperthermia at varioustime points. DNA DSB rejoining was measured usingasymmetric field inversion gel electrophoresis (AFIGE). TheDNA-PKcs activities were measured using DNA-PKcs enzymeassay system.RESULTS: Hyperthermia can significantly enhanceirradiation-killing cells. Thermal enhancement ratio ascalculated at 10 % survival was 2.02. The difference inradiosensitivity between two treatment modes manifestedas a difference in the α components and the almost sameβ components, which α value was considerably higher inthe cells of combined radiation and hyperthermia ascompared with irradiating cells (1.07 Gy-1 versus 0.44 Gy1). Survival fraction showed 1 logarithm increase after an8-hour interval between heat and irradiation, whereas DNA-PKcs activity did not show any recovery. The cells wereexposed to heat 5 minutes only, DNA-PKcs activity wasinhibited at the nadir, even though the exposure time waslengthened. Whereas the ability of DNA DSB rejoining wasinhibited with the increase of the length of hyperthermictime. The repair kinetics of DNA DSB rejoining aftertreatment with Wortmannin is different from thehyperthermic group due to the striking high slow rejoiningcomponent.CONCLUSION: Determination with the cell extracts andthe peptide phosphorylation assay, DNA-PKcs activity wasinactivated by heat treatment at 45.5 C, and could notrestore. Cell survival is not associated with the DNA-PKcsinactivity after heat. DNA-PKcs is not a unique factor affectingthe DNA DSB repair. This suggests that DNA-PKcs do notplay a crucial role in the enhancement of cellularradiosensitivity by hyperthermia. | Walter J.Curran George Iliakis | 2002 | World Journal of Gastroenterology2002，8，5： | 87 |
| 2 | Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis显示文摘AIM: To evaluate the efficacy of different treatment strategies for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and investigate factors influencing prognosis.METHODS: One hundred and seventy-nine HCC patients with macroscopic PVTT were enrolled in this study. They were divided into four groups and underwent different treatments: conservative treatment group (n = 18),chemotherapy group (n = 53), surgical resection group (n = 24) and surgical resection with postoperative chemotherapy group (n = 84). Survival rates of the patients were analyzed by the Kaplan-Meier method. A log-rank analysis was performed to identify group differences. Cox's proportional hazards model was used to analyze variables associated with survival.RESULTS: The mean survival periods of the patients in four groups were 3.6, 7.3, 10.1, and 15.1 mo respectively.There were significant differences in the survival rates among the groups. The survival rates at 0.5-, 1-, 2-, and 3-year in surgical resection with postoperative chemotherapy group were 55.8%, 39.3%, 30.4%, and 15.6% respectively, which were significantly higher than those of other groups (P<0.001). Multivariate analysis revealed that the strategy of treatment (P<0.001) and the number of chemotherapy cycles (P = 0.012) were independent survival predictors for patients with HCC and PVTT.CONCLUSION: Surgical resection of HCC and PVTT combined with postoperative chemotherapy or chemoembolization is the most effective therapeutic strategy for the patients who can tolerate operation.Multiple chemotherapeutic courses should be given postoperatively to the patients with good hepatic function reserve. | JiaFan JianZhou Zhi-QuanWu Shuang-JianQiu Xiao-YingWang Ying-HongShi Zhao-YouTang | 2005 | World Journal of Gastroenterology2005，11，8： | 58 |
| 3 | 门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究显示文摘目的探讨经皮肝门静脉内支架植入术(PTPVS)联合肝动脉化疗栓塞(TACE)治疗肝癌伴门静脉癌栓的临床疗效及安全性,并探索影响疗效的因素。方法 2009年1月-2010年10月在已临床确诊为肝癌伴门静脉癌栓患者中,按要求筛选病例62例,采用对照、非随机方法分为治疗组和对照组,对照组30例单接受TACE治疗;治疗组32例先接受PTPVS再行TACE治疗,其中2例病例放置门静脉支架未成功。评价指标为总生存时间和安全性。随访患者生存时间,并记录PTPVS术后并发症。用Kaplan-Meier生存分析法分析患者生存时间,两组间生存时间比较用Log-rank法检验;用Cox比例风险回归模型探讨影响患者临床预后的因素。结果治疗组中位总生存期为6.5个月,对照组中位总生存期为4.5个月(治疗组风险比为0.570,95%CI为0.328~0.992,P=0.037),两组间差异有统计学意义(P<0.05)。治疗组30例患者在3、6、12和18个月积累生存率分别为70%、56.7%、10%、3.3%。治疗组在术后1周内未出现手术相关并发症,远期出现的并发症有肝性脑病(2例,6.6%)、上消化道出血(呕血或黑便,3例,10%)、肝肾综合征(1例,3.3%)。结论在肝癌合并门静脉一级分支或(和)门静脉主干不完全闭塞癌栓患者中,PTPVS联合TACE治疗组中位生存期比单独TACE治疗组延长约2个月。治疗方案的安全性较好。 | 张磊 陆骊工 李勇 邵培坚 胡宝山 魏照光 何旭 禹娴怡 罗小宁 | 2011 | 介入放射学杂志2011，20，12： | 35 |
| 4 | Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE显示文摘AIM:To evaluate the role and limitation of fast multiplanarspoiled gradient-recalled (FMPSPGR) MR dynamiccontrast scanning in the follow-up of patients with HCCtreated by transarterial chemoembolization (TACE).METHODS:Twenty-two patients with 24 HCC lesionsconfirmed by biopsy or surgical resection underwentMR imaging in 4-9wks after TACE with a superconducting1.5 T MR scanner, including SE T1WI, T2WI and FMPSPGRdynamic contrast scanning. The signal intensities of alllesions on SE T1WI, T2WI and the enhancement patternson FMPSPGR dynamic contrast scanning were observed,and the comparison was made between MRI findingsand pathological results in ail the cases.RESULTS:Of the 24 lesions, the signal intensities werevarious on SE T1WI and T2WI. On T1WI, 13 lesionsappeared as hyperintense, 4 lesions were isointenseand the other 7 lesions were hypointensese.Histologically, hyperintense lesions showed on T1WIwere viable tumor or hemorrhage; isointensities werecoagulative necrosis or inflammatory infiltration;hypointensities were tumor, liquified necrosis,coagulative necrosis or inflammatory infiltration. OnT2WI, 15 lesions appeared as hyperintense, 3 lesionswere isointense and the other 6 lesions werehypointensese. Hyperintense lesions showed on T2WIwere residuals of viable tumor, hemorrhage, liquefiednecrosis or inflammatory infiltration; isointense lesionswere residuals of viable tumor or inflammatoryinfiltration; hypointense lesions were coagulativenecrosis. On FMPSPGR dynamic contrast scanning, 18of the 24 lesions enhanced on early-phase dynamicscanning conesponding to residuals of viable tumor andthe other 6 lesions had no enhancement at this phasebecause complete necrosis were seen in the histologicexamination. On delayed-phase dynamic scanning, 6lesions had permanent enhancement appeared asinhomogeneous hyperintensity and both residuals ofviable tumor and inflammatory infiltration were foundby histologic examination. 18 lesions were hypointenseat this phase and 8 of them coexisted with peripheralring-like enhancement of the lesions resulting fromviable tumors or inflammatory infiltration.CONCLUSION: FMPSPGR MR dynamic contrast scanningcan reflect the pathologic changes of HCC treated byTACE. Especially, early-phase dynamic scanning canevaluate accurately residuals of viable tumor andnecrosis in HCC lesions. FMPSPGR dynamic contrastscanning is useful in the follow-up of patients with HCCtreated by TACE combined with SE T1WI and T2WI, butit is difficult to differentiate peripheral viable tumorsfrom inflammatory infiltration. | Fu-Hua Yan Kang-Rong Zhou Jie-Min Cheng Jian-Hua Wang Zhi-Ping Yan Reng-Rong Da Department of Radiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China Jia Fan Department of Hepatobiliary-surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China Yuan Ji Department of Pathology,Zhongshan Hospital,Fudan University,Shanghai 200032,China | 2002 | World Journal of Gastroenterology2002，8，4： | 32 |
| 5 | 肝癌合并门静脉癌栓的治疗对策及疗效比较显示文摘目的 比较肝功能处于代偿期的肝癌合并门静脉癌栓患者不同治疗方法的疗效并探讨影响其疗效的因素。 方法 138例肝功能处于代偿期、术前估计可以手术切除的门静脉癌栓患者 ,根据不同的治疗方法分成 4组 :保守治疗组 14例、化疗组 4 1例、手术切除组 19例、手术切除加化疗组6 4例。 结果 保守治疗组中位生存时间 3 5个月 ;化疗组中位生存时间 7 1个月 ;手术切除组中位生存时间 10 3个月 ;而手术切除加化疗组中位生存时间 13 4个月 ,术后半年 0 5、1、2、3年生存率分别为 5 3 7%、37 6 %、30 7%、14 0 % ,明显高于其他 3组 (P <0 0 5 )。单因素、多因素分析提示术后化疗次数是影响手术切除后疗效的重要因素。 结论 (1)门静脉癌栓患者在肝功能处于代偿期 ,术前估计手术能一并切除原发灶与癌栓时 ,应行剖腹探查 ,而手术切除加术后化疗的疗效最好 ;(2 )术后在患者肝功能许可的情况下 ,可行多次栓塞化疗。 | 樊嘉 吴志全 周俭 邱双健 陈荣新 史颖弘 汤钊猷 | 2003 | 中华外科杂志2003，41，11： | 34 |
| 6 | Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma显示文摘AIM:To evaluate long-term effect of ethanol embolization for the treatment of hepatocellular carcinoma (HCC) with severe hepatic arterioportal shunt (APS), compared with Gelfoam embolization.METHODS:Sixty-four patients (ethanol group) and 33 patients (Gelfoam group) with HCC and APS were respectively treated with ethanol and Gelfoam for APS before the routine interventional treatment for the tumor. Frequency of recanalization of shunt, complete occlusion of the shunt,side effects, complications, and survival rates were analyzed between the two groups.RESULTS: The occlusion rate of APS after initial treatment in ethanol group was 70.3%(45/64), and recanalization rate of 1 month after embolization was 17.8%(8/45),and complete occlusion rate was 82.8%(53/64).Those in Gelfoam group were 63.6%(21/33), 85.7%(18/21), and 18.2%(6/33).There were significant differences in recanalization rate and complete occlusion rate between the two groups (P<0.05).The survival rates in ethanol group were 78% at 6 months,49% at 12 months, 25% at 24 months, whereas those in Gelfoam group were 58% at 6 months, 23% at 12 months,15% at 24 months.The ethanol group showed significantly better survival than Gelfoam group (P<0.05). In the ethanol group, there was a significant prolongation of survival in patients with monofocal HCC (P<0.05) and Child class A (P<0.05).There were no significant differences in survival rate in the Gelfoam group with regard to the number of tumor and Child class (P>0.05). The incidence rate of abdominal pain during procedure in ethanol group was 82.8%.There was no significant difference in postembolization syndromes between two groups. Procedure-related hepatic failure did not occur in ethanol group.CONCLUSION: Ethanol embolization for patients with HCC and severe APS is efficacious and safe, and may contribute to prolongation of the life span versus Gelfoam embolization. | Ming-ShengHuang QuLin Zai-BoJiang Kang-ShunZhu Shou-HaiGuan Zheng-RanLi HongShan | 2004 | World Journal of Gastroenterology2004，10，6： | 30 |
| 7 | 肝癌合并门静脉癌栓的诊治进展显示文摘门静脉癌栓是影响肝癌患者预后的最重要因素之一。文章系统回顾了门静脉癌栓的形成机制、诊断及治疗方面的进展。虽然癌栓可通过影像学检查(尤其是术中B超)得以发现,但癌栓治疗效果一直不能令人满意。术中肿瘤切除加门静脉取栓、加术后肝动脉、门静脉双灌注化疗等综合治疗是目前应用较多的疗法。 | 薛峰 沈锋 吴孟超 | 2005 | 中国肿瘤2005，14，3： | 26 |
| 8 | Effects of p53 on apoptosis and proliferation of hepatocellular cardnoma cells heated with transcatheter arterial chemoembolization显示文摘AIM:To evaluate the effects of p53 on apoptosis and proliferation of hepatocellular carcinoma (HCC) cells treated with transcatheter arterial chemoernbolization (TACE).METHODS: A total of 136 patients with HCC received TACE and other management before surgery were divided into TACE group and non-TACE group.TACE group included 79 patients who had 1-5 courses of TACE before surgery,of them,11 patients had 1-4 courses of chemotherapy (group A),33 patients had 1-5 courses of chemotherapy combined with iodized oil (group B), 23 patients had 1-3 courses of chemotherapy,iodized oil and gelatin sponge (group C),12 patients had 1-3 courses of chemotherapy combined with iodized oil,ethanol and gelatin sponge (group D).Non-TACE group included the remaining 57 patients who had surgery only.The extent of apoptosis was analyzed by transferase mediated dUTP nick end labeling (TUNEL) staining.The expressions of p53, Bcl-2,Bax,Ki-67 and PCNA protein were detected by immunohistochemical method.RESULTS: P53 protein expressions in trabecular and clear cells in HCC specimens were significantly lower than that in pseudoglandar, solid, poorly differentiated or undifferentiated and sclerosis HCC (P<0.05) Expression of p53 protein in HCC cells increased with the increase of pathological grades(P<0.05),and correlated positively with expressions of Ki-67 and PCNA protein,and negatively with Bcl-2 to Bax protein expression rate and AI (P<0.05).Expression of p53 protein was significantly higher in group A than in groups B, C, D and the non-TACE group, and was higher in group B than in groups C and D,and lower in group D than in the non-TACE group (P<0.05).CONCLUSION:Expression of p53 protein can enhance proliferation of HCC cells and suppress apoptosis of HCC cells after TACE. | En-HuaXiao Jing-QingLi Jie-FuHuang | 2004 | World Journal of Gastroenterology2004，10，2： | 26 |
| 9 | 原发性肝癌合并门静脉癌栓的治疗现状显示文摘 | 张伟杰 杨甲梅 | 2005 | 肝胆外科杂志2005，13，4： | 24 |
| 10 | 肝细胞肝癌伴门静脉下腔静脉癌栓接受与不接受放射治疗的比较显示文摘目的探讨肝细胞肝癌患者伴门静脉和或下腔静脉癌栓接受外放射治疗的疗效。方法回顾总结近8年180例原发性肝细胞肝癌伴门静脉和或下腔静脉癌栓患者,其中66例接受直线加速器外放疗作为放疗组,114例未接受外放疗作为对照组,放疗组与对照组间影响患者的主要预后因素除肿瘤标志物有差别外,其他因素无明显差别。放疗组放疗方法为常规分割,局部放疗癌栓,放射治疗剂量介于36~60Gy(中位50Gy)。放射治疗中及治疗后随访肝功能、影像学检查和生存情况。应用Cox回归模型,多因素分析比较两组的生存期。结果66例癌栓患者接受外放射治疗,22例(33.3%)患者癌栓完全缓解,16例(24.2%)部分缓解,26例(39.4%)稳定,2例(3.1%)进展;1年生存率27.9%,中位生存期7.3个月。对照组1年生存率为12.3%,中位生存期为4个月。多因素回归分析显示,外放射治疗显示出很强的保护因素(RR=0.408,P<0.001)。放疗组病人生存情况与甲胎蛋白水平无关;但与γ-GT水平、肝内病灶单多发、癌栓存在的部位有关。死亡原因多为肝内肿瘤未控制导致肝衰。对照组下腔静脉系统癌栓患者生存情况比门静脉癌栓患者差,相反,放疗组下腔静脉癌栓患者的生存情况好于门静脉癌栓患者。结论结合外放射治疗可明显延长肝细胞肝癌伴有门静脉和或下腔静脉癌栓患者的生存期,肝内原发肿瘤灶为单发的癌栓患者,放射治疗更能延长其生存期。 | 曾昭冲 汤钊猷 樊嘉 周俭 钦伦秀 叶胜龙 王建华 王斌樑 王小林 | 2006 | 癌症进展2006，4，4： | 20 |
| 11 | 肝癌供血的特点及其在介入治疗中的意义显示文摘肝癌是最难治疗的恶性肿瘤之一。目前介入治疗已成为肝癌的重要治疗手段。充分了解肝癌的供血方式,对提高介入治疗效果具有重要意义。肝癌一般有动脉和门静脉双重供血,85%~90%来源于肝动脉(以腹腔—肝动脉型供血最常见,占80%),异位肝动脉供血约占20%,非肝动脉供血较少见,以膈下动脉常见。肝癌门静脉供血成分较少,但当肝动脉栓塞后门静脉血流将增加,因而提出肝癌的介入治疗采用肝动脉与门静脉“双栓”的做法。肝动脉—门静脉瘘及肝动脉—肝静脉瘘对肝癌的血供亦具影响,但并非肝动脉栓塞的禁忌证。对门静脉癌栓予以积极地超选择性化疗加栓塞,将有助于提高肝癌患者的生存期。 | 高宗恩 张承勋 庞闽厦 孙鹏 | 2001 | 世界华人消化杂志2001，9，12： | 18 |
| 12 | 低分割三维适形放射结合介入治疗肝细胞癌伴门静脉癌栓的疗效显示文摘背景与目的肝细胞癌常伴有门静脉癌栓且预后极差,有学者用三维适形放射治疗常规剂量分割模式进行治疗取得了较好的疗效。本研究的目的是评价低分割三维适形放射治疗(3-dimensionalconformalradiationtherapy,3DCRT)结合经皮肝动脉化疗栓塞(transcatheterarterialchemoembolization,TACE)治疗肝细胞癌(hepatocellularcarcinoma,HCC)伴门静脉癌栓(portalveintumorthrombus,PVTT)的疗效。方法对35例不能手术切除的HCC伴PVTT患者,采用低分割3DCRT结合TACE进行治疗,根据肿瘤体积大小,放射采用每次4~8Gy,3次/周;48~60Gy,8~12分次,3.0~3.5周完成。观察近期疗效,用Kaplan-Meier法进行生存分析,采用Cox比例风险模型作多因素分析。结果肿瘤缓解率为71.4%,1、2、3年累积生存率分别是59.3%、31.6%、26.6%,中位生存期11个月。多因素分析显示Child分级是影响预后的主要因素(P<0.05)。放射性肝炎和胃肠道出血是最常见的并发症。结论大分割3DCRT结合TACE治疗HCC伴PVTT有较好的疗效。肝功能Child分级与患者的预后有密切关系。 | 吴德华 陈龙华 | 2004 | 癌症2004，23，7： | 18 |
| 13 | 肝癌合并门静脉癌栓的TACE治疗显示文摘经导管动脉化疗栓塞术(TACE)已广泛应用于无法切除的肝癌,也应用于合并门静脉癌栓(PVTT)的肝癌。为此,笔者就TACE在合并PVTT肝癌中的应用,及其并发症与待完善的方面等进行综述。 | 江海中 邓新 钟永富 | 2015 | 中国普通外科杂志2015，24，1： | 17 |
| 14 | Role of preoperative selective portal vein embolization in two-step curative hepatectomy for hepatocellular carcinoma显示文摘AIM: To determine the feasibility and role of ultrasoundguided preoperative selective portal vein embolization (POSPVE) in the two-step hepatectomy of patients with advanced primary hepatocellular carcinoma (HCC).METHODS: Fifty patients with advanced HCC who were not suitable for curative hepatectomy were treated by ultrasound-guided percutaneous transhepatic POSPVE with fine needles. The successful rate, side effects and complications of POSPVE, changes of hepatic lobe volume and two-step curative hepatectomy rate after POSPVE were observed.RESULTS: POSPVE was successfully performed in 47(94.0 %) patients. In patients whose right portal vein branches were embolized, their right hepatic volume decreased and left hepatic volume increased gradually. The ratio of right hepatic volume to total hepatic volume decreased from 62.4 % before POSPVE to 60.5 %, 57.2 %and 52.8 % after 1, 2 and 3 weeks respectively. The side effects included different degree of pain in liver area (38cases), slight fever (27 cases), nausea and vomiting (9cases). The level of aspartate alanine transaminase (AST),alanine transaminase (ALT) and total bilirubin (TBIL)increased after POSPVE, but returned to preoperative level in 1 week. After 2-4 weeks, two-step curative hepatectomy for HCC was successfully performed on 23 (52.3 %) patients.There were no such severe complications as ectopic embolization, local hemorrhage and bile leakage.CONCLUSION: Ultrasound-guided percutaneous transhepatic POSPVE with fine needles is feasible and safe. It can extend the indications of curative hepatectomy of HCC, and increase the safety of hepatectomy. | WuJi Jie-ShouLi Ung-TangLi Wu-HongLiu Kuan-ShengMa Xiang-TianWang Zhen-PingHe Jia-HongDong | 2003 | World Journal of Gastroenterology2003，9，8： | 15 |
| 15 | 肝细胞癌合并血管侵犯专家共识(讨论稿)显示文摘肝细胞癌合并血管侵犯是影响肝细胞癌预后的重要因素。血管侵犯分为大血管侵犯(macrovascular invasion)和微小血管侵犯(microvascular invasion,以下简称m VI)。大血管侵犯指门静脉及其主要分支形成的癌栓(portal vein tumor thrombus,以下简称PVTT)。而m VI尚无明确统一定义,多指癌栓位于门静脉终末分支(portal radicle vein)。 | | 2015 | 肝癌电子杂志2015，2，3： | 15 |
| 16 | Percutaneous transsplenic embolization of esophageal and gastrio-fundal varices in 18 patients显示文摘AIM: Clinical application and potential complication of percutaneous transsplenic varices embolization (PTSVE) of esophageal or gastrio-fundal varices in patients with hepatocellular carcinoma (HCC) complicated with portal vein cancerous thrombosis (PVCT).METHODS: 18 patients with HCC complicated with PVCT and esophageal or gastrio-fundal varices who underwent PTSVE were collected. The rate of success, complication, mortality of the procedure and postoperative complication were recorded and analyzed.RESULTS: PTSVE were successfully performed in 16 of 18cases, and the rate of success was 89%. After therapy erythrocyte counts decreased in all of the natunts. 5 of patients needed blood transfusion, 2 patients requiredsurgical intervention because of and 11 patients with ascites were alleviated by diuresis. Among these 18patients, the procedure-related mortality was 11% (2/18),one died of acute hepatic failure on the forth day after procedure, another died of acute renal failure on the fifth day. The patients were follow up for 112 mon exceptone. 13of them died of their tumors but none of them experienced variceal bleeding.CONCLUSION: PTSVE is a relatively safe and effective method to treat esophageal or gastrio-fundal varices in HCCpatients with PVCT when percutaneous transhepatic varices embolization (PTHVE) of varices is impossible. | Gao-Quan Gong Xiao-Lin Wang Jian-Hua Wang Zhi-Ping Yan Jie-Min Cheng Sheng Qian Yi Chen Department of Radiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China | 2001 | World Journal of Gastroenterology2001，7，6： | 14 |
| 17 | Pathological characteristics,PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma显示文摘AIM:To study the relationship between prognosis and pathological characteristics,proliferating cell nuclear antigen labelin index(PCNA-LI)and DNA index(DI)in patients with moderately differentiated hepatocellular carcinorma(HCC). | Wen-JiaoZeng Guo-YuanLiu JieXu Xin-DaZhou Yue-EZhang NongZhang | 2002 | World Journal of Gastroenterology2002，8，6： | 13 |
| 18 | Experimental study on therapeutic effect of in vivo expression of Cell Ⅰ-Hep Ⅱ recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma显示文摘AIM: To investigate the inhibitory effect of in vivoexpression of expressing plasmid pCH510 of recombinant fibronectin polypeptide (CH50) on hepatocellular carcinoma and the improved therapeutic effect of pCH510 in combination with chemotherapeutic agents and Hsp70-H22 hepatocarcinoma antigen peptide on tumor.METHODS: Mice were inoculated with H22 hepatccarcinoma cells. The chemotactic effect of the expression of plasmid pCH510 on immunocytes was observed after in vivo transfection, tissue slicing and HE staining. Inhibitory effect of transfection with pCH510 on routine tumor originatedfrom different inoculative doses was observed. The inhibitory effect of immediate transfection with pCH510 after chemotherapy on tumor was compared with that of transfection 5 days after chemotherapy. The change of function and amount of mouse peritoneal macrophages and the peripheral blood immunocytes resulted from administration of chemotherapeutic agents were detected. The peptides mixture was prepared from H22 hepatocarcinoma cells, pCH510 + Hsp70-H22 antigen peptides were injected into tumor-bearing mice with or without chemotherapy, to observe the inhibitory effects on tumor.RESULTS: At the tumor tissue site injected with pCH510,there were a great number of immunocytes which mainly were macrophages, lymphocytes and neutrophils.Transfection of plasmid pCH510 inhibited significantly the murine tumor induced by different inoculative doses. The inhibitory effect was negatively correlated with the inoculative dose. The therapeutic effect was not improved by immediate transfection with pCH510 after chemotherapy, but was significantly improved by transfection with pCH510 5 days after chemotherapy. Chemotherapeutic agent decreased the number of immunocytes and suppressed their activation in vivo. After injection of drug, the amount of immunocytes was the lowest from d 1 to d 3 and returned to normal level on the 10th day. Transfection with plasmid pCH510 alone could inhibit tumor induced by the inoculation with 10^4 H22 cells. The tumor originated from the inoculation with 10^5 H22 cells was inhibited by pCH510+Hsp70-H22 antigen peptides and that from the inoculation with 10^6 H22 cells was inhibited by pCH510+HspT0-H22 antigen peptides in combination with chemotherapeutic agents.CONCLUSION: In vivo expression of pCH510 recruits immune cells, inhibits tumor growth, and enhances the efficacy of chemotherapy, But the proper timing of combining chemotherapy with pCH510 must be taken into great account, The synergism of pCH510 and Hsp70-H22 peptides can improve the efficacy, which could be further enhanced if they are used following chemotherapy, Chemotherapeutic agent + pCH510 + Hsp70-H22 peptides is a promising therapeutic approach of combination treatment of tumor, | Gui-Mei Zhang Yan Yang Bo Huang Hui Xiao Dong Li Zuo-Hua Feng Department of Biochemistry and Molecular Biology,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei Province,China | 2003 | World Journal of Gastroenterology2003，9，9： | 13 |
| 19 | 肝癌合并门静脉癌栓的治疗方法及价值显示文摘 | 王晓颖 樊嘉 | 2009 | 肝胆外科杂志2009，17，1： | 12 |
| 20 | 肝癌外科治疗的进展显示文摘本文简述2000年以来国外文献和复旦大学肝癌研究所的部分工作.小肝癌切除的疗效继续得到公认,局部治疗的疗效虽未超过切除,但未来将部分取代切除.微创外科和微创外科观念值得重视.肝癌筛查可使更多患者获得治疗机会.肝癌切除的禁区已基本攻克,未来将更多研究对合并肝内静脉癌栓的外科综合治疗.临床肝癌中不能切除者仍将占多数,由于局部治疗的进步,不能切除肝癌的降期后(缩小后)切除是部分不能切除肝癌的一条出路.对于小肝癌,肝移植的无瘤生存率高于切除者,故其作用将缓慢上升.21世纪肝癌转移复发的研究将成为重点,目前在转移复发预测和预防方面已有不少进展,但成为临床常规还有待时日.随机分组试验和荟萃分析是推动肝癌外科进步的必由之路. | 汤钊猷 | 2003 | 世界华人消化杂志2003，11，3： | 12 |
您所在的机构暂未开通此部分的功能，请联系管理员